Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Sci Rep. 2020 May 29;10(1):8778. doi: 10.1038/s41598-020-65833-0.
This prospective clinical study was to compare the effect of panretinal photocoagulation (PRP) associated with intravitreal conbercept injections versus PRP alone in the treatment of proliferative diabetic retinopathy (PDR). For each of 15 patients included, one eye was randomly assigned to receive treatment with PRP, and the other eye received conbercept combined PRP. Ophthalmic examinations, optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) were performed at baseline and at each monthly visit until 6 months. Fluorescein angiography (FA) was acquired at baseline, 3 months and 6 months. Between group and within group analysis was done by using generalized estimating equations (GEE). The combination group had a significant decrease of neovascularization (NV) leakage area than the PRP group at month 3 and month 6 after treatment, and a better best-corrected visual acuity (BCVA) during the first three months. Within-group analysis indicated a significant decrease in NV leakage at month 3 and month 6 in both groups, and a significant increase in BCVA at 1 month in the combination group. In summary, the combination of intravitreal injection of conbercept and PRP can significantly reduce the NV of PDR patients and achieve better BCVA during the drug's lifespan compared with PRP alone.
本前瞻性临床研究旨在比较全视网膜光凝（PRP）联合玻璃体腔注射康柏西普与单纯 PRP 治疗增生型糖尿病视网膜病变（PDR）的疗效。将 15 例患者中的每例患者随机分为两组，一组接受 PRP 治疗，另一组接受康柏西普联合 PRP 治疗。两组患者均在基线和每月随访时进行眼科检查、光学相干断层扫描（OCT）和光学相干断层扫描血管造影（OCTA）检查，直至 6 个月。在基线、3 个月和 6 个月时采集荧光素眼底血管造影（FA）图像。采用广义估计方程（GEE）进行组间和组内分析。治疗 3 个月和 6 个月后，联合组新生血管（NV）渗漏面积明显低于 PRP 组，且在前 3 个月最佳矫正视力（BCVA）更好。组内分析显示，两组 NV 渗漏在治疗 3 个月和 6 个月时均明显减少，联合组在治疗 1 个月时 BCVA 明显增加。综上所述，与单纯 PRP 治疗相比，玻璃体腔注射康柏西普联合 PRP 可显著减少 PDR 患者的 NV，并在药物作用期间获得更好的 BCVA。
